LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• LivaNova PLC has been given an average recommendation of "Moderate Buy", with a consensus target price of $59.71 among analysts.
• The company reported $1.05 EPS for its most recent quarter, surpassing estimates, and experienced a 10.6% year-over-year revenue increase to $352.50 million.
• Institutional investors hold 97.64% of LivaNova's stock, indicating strong confidence from larger financial entities.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $59.7143.

A number of research analysts have recently commented on LIVN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of LivaNova in a research report on Wednesday, October 8th. Barclays raised their target price on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a "neutral" rating in a research report on Wednesday, October 1st. Finally, Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th.

Institutional Trading of LivaNova

A number of hedge funds have recently made changes to their positions in LIVN. Principal Financial Group Inc. raised its position in LivaNova by 2.1% during the first quarter. Principal Financial Group Inc. now owns 179,546 shares of the company's stock valued at $7,053,000 after purchasing an additional 3,668 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of LivaNova by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company's stock valued at $1,840,000 after buying an additional 2,901 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in LivaNova by 2.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock worth $817,000 after buying an additional 500 shares during the last quarter. New York State Common Retirement Fund boosted its stake in LivaNova by 28.6% in the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock worth $1,897,000 after buying an additional 10,733 shares in the last quarter. Finally, CWM LLC boosted its stake in LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after buying an additional 299 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Performance

NASDAQ LIVN opened at $54.45 on Friday. The company has a market capitalization of $2.97 billion, a PE ratio of -14.00 and a beta of 0.95. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. LivaNova has a 52-week low of $32.48 and a 52-week high of $58.91. The company has a 50-day simple moving average of $54.51 and a 200 day simple moving average of $46.81.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. During the same quarter last year, the business posted $0.93 EPS. LivaNova's quarterly revenue was up 10.6% compared to the same quarter last year. On average, research analysts predict that LivaNova will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.